Portside Wealth Group LLC Has $550,000 Stake in West Pharmaceutical Services, Inc. $WST

Portside Wealth Group LLC lessened its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 23.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,513 shares of the medical instruments supplier’s stock after selling 785 shares during the period. Portside Wealth Group LLC’s holdings in West Pharmaceutical Services were worth $550,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SYM FINANCIAL Corp increased its stake in West Pharmaceutical Services by 5.1% in the second quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier’s stock valued at $225,000 after purchasing an additional 50 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of West Pharmaceutical Services by 4.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,318 shares of the medical instruments supplier’s stock valued at $288,000 after buying an additional 51 shares during the period. MJP Associates Inc. ADV increased its position in West Pharmaceutical Services by 2.7% in the 2nd quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier’s stock valued at $431,000 after buying an additional 52 shares in the last quarter. Horizon Investments LLC increased its position in West Pharmaceutical Services by 5.8% in the 1st quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $234,000 after buying an additional 57 shares in the last quarter. Finally, Pallas Capital Advisors LLC raised its stake in West Pharmaceutical Services by 1.0% during the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier’s stock worth $1,386,000 after buying an additional 62 shares during the period. 93.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. KeyCorp boosted their price target on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, October 24th. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Tuesday, October 14th. Redburn Partners set a $311.00 price objective on shares of West Pharmaceutical Services in a report on Monday, September 15th. Finally, Deutsche Bank Aktiengesellschaft set a $345.00 target price on shares of West Pharmaceutical Services and gave the stock a “buy” rating in a research report on Friday, October 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, West Pharmaceutical Services currently has a consensus rating of “Moderate Buy” and a consensus target price of $349.20.

West Pharmaceutical Services Price Performance

WST opened at $260.08 on Wednesday. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $348.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. The company has a market capitalization of $18.71 billion, a price-to-earnings ratio of 38.53, a P/E/G ratio of 4.09 and a beta of 1.08. The firm’s fifty day moving average price is $269.06 and its two-hundred day moving average price is $242.69.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The company had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. During the same period last year, the firm earned $1.85 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.